subscribeSubscribe
price-trendAsk Us
ESMO: Lilly`s RET drug shrinks half of rare thyroid cancers

ESMO: Lilly`s RET drug shrinks half of rare thyroid cancers
A. Al Idrus FIERCE BIOTECH
30 Sep 2019
Share Share
Lilly`s RET drug shrinks more than half of rare thyroid cancers

Lilly`s RET drug shrinks more than half of rare thyroid cancers
Amirah Al Idrus FIERCE BIOTECH
29 Sep 2019
Share Share
Shrinking 60% of lung cancers, Blueprint`s RET drug poised for 2020 filing

Shrinking 60% of lung cancers, Blueprint`s RET drug poised for 2020 filing
Amirah Al Idrus FIERCE BIOTECH
04 Jun 2019
Share Share
NICE looks to toss Sanofi, Ipsen thyroid cancer drugs from CDF

NICE looks to toss Sanofi, Ipsen thyroid cancer drugs from CDF
Eric Palmer FIERCE PHARMA
24 Aug 2017
Share Share
NICE rejects thyroid cancer drugs

NICE rejects thyroid cancer drugs
Selina McKee PHARMA TIMES
23 Aug 2017
Share Share
AstraZeneca Completes Divestment Of Caprelsa To Genzyme

AstraZeneca Completes Divestment Of Caprelsa To Genzyme
NASDAQ
06 Oct 2015
Share Share
AstraZeneca tops Q2 estimates on strength of diabetes drugs and clot-buster Brilinta

AstraZeneca tops Q2 estimates on strength of diabetes drugs and clot-buster Brilinta
Arlene Weintraub FIERCE PHARMA
30 Jul 2015
Share Share
Genzyme Strengthens Endocrinology Portfolio with Acquisition of Caprelsa® (vandetanib) from AstraZeneca

Genzyme Strengthens Endocrinology Portfolio with Acquisition of Caprelsa® (vandetanib) from AstraZeneca
BUSINESS WIRE
27 Jul 2015
Share Share